Tower Research Capital (TRC)’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-13,928
| Closed | -$336K | – | 6598 |
|
|
2023
Q1 | $336K | Buy |
13,928
+13,553
| +3,614% | +$170K | 0.01% | 1076 |
|
|
2022
Q4 | $4K | Sell |
375
-26,164
| -99% | -$211K | ﹤0.01% | 5132 |
|
|
2022
Q3 | $119K | Buy |
26,539
+18,180
| +217% | +$82.8K | ﹤0.01% | 2426 |
|
|
2022
Q2 | $33K | Buy |
8,359
+2,035
| +32% | +$9.65K | ﹤0.01% | 3289 |
|
|
2022
Q1 | $46K | Buy |
6,324
+1,379
| +28% | +$8.25K | ﹤0.01% | 2812 |
|
|
2021
Q4 | $28K | Buy |
4,945
+592
| +14% | +$3.76K | ﹤0.01% | 3322 |
|
|
2021
Q3 | $28K | Buy |
4,353
+518
| +14% | +$3.33K | ﹤0.01% | 3441 |
|
|
2021
Q2 | $32K | Sell |
3,835
-12,928
| -77% | -$104K | ﹤0.01% | 3437 |
|
|
2021
Q1 | $176K | Buy |
16,763
+13,457
| +407% | +$189K | ﹤0.01% | 2126 |
|
|
2020
Q4 | $56K | Sell |
3,306
-36,945
| -92% | -$554K | ﹤0.01% | 3007 |
|
|
2020
Q3 | $516K | Buy |
40,251
+38,147
| +1,813% | +$482K | 0.01% | 1649 |
|
|
2020
Q2 | $30K | Buy |
+2,104
| New | +$26.6K | ﹤0.01% | 3447 |
|
|
2020
Q1 | – | Sell |
-7,301
| Closed | -$109K | – | 4178 |
|
|
2019
Q4 | $109K | Sell |
7,301
-12,844
| -64% | -$114K | 0.01% | 889 |
|
|
2019
Q3 | $137K | Buy |
+20,145
| New | +$204K | 0.01% | 1182 |
|
|
2019
Q2 | – | Sell |
-960
| Closed | -$2K | – | 4504 |
|
|
2019
Q1 | $2K | Sell |
960
-2,257
| -70% | -$5.3K | ﹤0.01% | 3488 |
|
|
2018
Q4 | $6K | Sell |
3,217
-1,955
| -38% | -$5.62K | ﹤0.01% | 2838 |
|
|
2018
Q3 | $21K | Buy |
+5,172
| New | +$20.4K | ﹤0.01% | 2320 |
|
Other funds holding PRVB
Tower Research Capital (TRC)'s PRVB Position: Q2 2023 in Review
Tower Research Capital (TRC) sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 13,928 shares — an estimated $336K sold.
Tower Research Capital (TRC) first reported a position in PRVB in Q3 2018 and held it in 17 quarters. The position peaked at $516K in Q3 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Tower Research Capital (TRC) reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 13,928 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $336K.
- Tower Research Capital (TRC) first reported a position in Provention Bio, Inc. Common Stock in Q3 2018 and held it in 17 quarters.
- Tower Research Capital (TRC)'s Provention Bio, Inc. Common Stock position peaked at $516K in Q3 2020.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.